Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently.

• Mixed-HSCT后应用DLI+IL-2,可能是有效提高长期生存率的免疫生物治疗措施之一。